Lupin Ltd

Lupin Earnings Call Transcript: Key Takeaways

Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.

Lupin Investor Presentation: Key Takeaways

Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.

Lupin Management Change

Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.

Lupin Q2 FY27 Results: Net Profit ₹1,155 Cr, Down 22.2% YoY

Lupin Ltd reported revenue from operations of ₹7,827 Cr (+11.1% YoY) and net profit of ₹1,155 Cr (-22.2% YoY) for Q2 FY27.

Key figure

Net profit ₹1,155 Cr · -22.2% YoY

Lupin Product Launch

Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.

Lupin Regulatory Approval

Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.

Lupin Business Update

Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.

Lupin Management Change

Lupin Limited appointed Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. He will oversee global legal, compliance, and IP functions.

Lupin Employee Stock Options

Lupin Limited has granted 40,157 stock options to employees under its existing ESOP scheme at an exercise price of ₹2.00 per share.

Lupin Board Meeting Date

Lupin Limited scheduled a Board meeting on November 03, 2026, to consider and approve its unaudited standalone and consolidated financial results.

Lupin Other Announcement

Lupin Limited received an ESG rating of 70 for FY26 from NSE Sustainability Ratings and Analytics. The assessment was independently prepared using publicly available information.

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

Lupin Product Launch

Lupin Limited launched Formoflo-G® MDI, the world's first fixed-dose triple combination inhaler for COPD management in India. This follows approval from the Drug Controller General of India.

Lupin Merger & Restructuring

Lupin Limited's step-down subsidiary, Multicare Pharmaceuticals Philippines, Inc., completed a buyback of 30,559 shares. MPPI is now a wholly owned step-down subsidiary of the Company.

Lupin Regulatory Approval

Lupin Limited received tentative approval from the U.S. FDA for its Apixaban Oral Suspension 1.25mg/mL. The product will be manufactured at the company's New Jersey facility.

From

U.S. Food and Drug Administration (U.S. FDA)

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.

Lupin Employee Stock Options

Lupin Limited allotted 30,967 equity shares under its Employee Stock Option Plan. This allotment increases the company's total issued and paid-up equity share capital.

Lupin Other Announcement

Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.

Lupin Partnership

Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.

Value

₹832.5 Cr

Execution

Initial term until 20th anniversary of first commercial sale

Lupin Management Change

Lupin Limited announced the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026.

Lupin Regulatory Approval

Lupin received U.S. FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension. The drug treats hyperkalemia in adults.

Lupin Earnings Call Transcript: Key Takeaways

Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.

Lupin Investor Presentation: Key Takeaways

Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.

Lupin Q1 FY27 Results: Net Profit ₹1,415 Cr, Up 16.1% YoY

Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,415 Cr (+16.1% YoY) for Q1 FY27.

Key figure

Net profit ₹1,415 Cr · +16.1% YoY

Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY

Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1,417 Cr · +16.0% YoY

Lupin Annual General Meeting

Lupin Limited held its 44th Annual General Meeting on August 04, 2026. All proposed resolutions, including dividend declaration, were passed with the requisite majority.

Lupin Business Update

Lupin received US FDA approval for its Diazepam Injection, USP, enabling its commercialization in the U.S. market.

Lupin Product Launch

Lupin Limited has launched Sugammadex Injection in the United States following U.S. FDA approval. The product is a bioequivalent to Merck's Bridion® for reversing neuromuscular blockade.

Lupin Board Meeting Date

Lupin Limited has scheduled a Board Meeting for August 06, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.